CD79A and type 2 diabetes mellitus: Neither IAPPM-IgA nor IAPPO-IgA levels differed between T2D management strategy groups at baseline (p = 0.854 and p = 0.287, respectively), after 3 months (p = 0.802 and p = 0.341, respectively), or at the clinical follow-up (p = 0.395 and p = 0.690, respectively).